A big warm welcome to our new #members: @talksmediagroup Source BioScience Transform Executive Coaching CMCL Gallagher UK Semarion Lucida Medical YPMH Cambridge Heartwear Not a member? Find out more: ow.ly/75k050I5yGR

We are looking forward to One Nucleus' careers conference tomorrow. As before they are bringing together some great organizations, people, and talks. Connect with us there! Tickets: onenucleus.com/civicrm/event/… Our vacancies: semarion.com/careers/

Semarion is looking for a Cell Biology Lead 🧪 Have post-doctoral experience in working on drug discovery related projects? Apply here 👇 semarion.com/job/lead-cell-…

Congratulations to all #21toWatch! We're delighted to see so many familiar faces & Cambridge University spin-outs in the group, including Semarion Psyomics flusso HexagonFab Porotech Cambridge GaN Devices Sano Genetics Jonathan Heeney #DIOSynVax #DeepForm cambridgeindependent.co.uk/business/21tow…

I am delighted to have made it to cofinitive's #21toWatch final Top21.2022. Yesterday's event brought together a wonderful group of people. Check out the Cambridge Independent article to find out more: cambridgeindependent.co.uk/business/21tow…

In case you missed it, Dr Jeroen Verheyen, Co-Founder and CEO of one of our portfolio companies, Semarion , has recently been highlighted in the #21toWarch Top21 list of standout individuals by cofinitive! bit.ly/3t9TI5A

Info on #MilnerSymp22's panel is live! Chaired by Kristin-Anne Rutter & including: - Andy Neely - Michael Anstey - Jamie Blundell - Jeroen Verheyen - Victoria Higgins milner.cam.ac.uk/milner-symposi… Cambridge Innovation Capital Cambridge University CUHP Andy Neely Jamie Blundell Jeroen Verheyen GSK

This episode of Connect: Health Tech's Joining the Dots podcast explores the theme of taking research from idea to proof of concept and beyond. Exclusively on Connect: Health Tech. lnkd.in/gu-gXfjB

This week we're highlighting #21toWatch Top21.2022 winner Jeroen Verheyen. Jeroen is co-founder and CEO at Semarion, a Cambridge spin-out which brings together material science and cell biology to solve key bottlenecks in drug discovery cofinitive.com/21towatch/

Our CEO, Dr Jason Mellad, and Dr Jeroen Verheyen, CEO of Stephen Marion, shared their career journeys, thoughts on future #healthcare #innovations and #commercialising #research, at Connect: Health Tech #podcast launched by the Milner Therapeutics Institute. Catch up here: bit.ly/3swYSbb

In this year’s symposium by Milner Therapeutics Institute, Dr Jeroen Verheyen, CEO of our portfolio company Semarion, will be part of a panel discussing the future of interdisciplinary interactions between #academia and #industry: lnkd.in/eA8jgHCT #MilnerSymp22 #CambridgeScience

Come and join us at the Panel on "Shaping the future of interdisciplinary interactions"!

Collaborations, collaborations and more collaborations….great to hear from our diverse and experienced panel on what successful partnerships have looked like for them and hear how best to maximise collaborative potential #MilnerSymp22

The CEO’s of our portfolio companies Semarion and Enhanc3D Genomics are speaking at One Nucleus’ #ONHelix22 conference taking place on July 7th in #Cambridge. Find more information about this year's theme and agenda here: onhelix.com

Seasonal greetings from Semarion. We had a little little bit of fun with our cell microcarriers. Have a look at the video and enjoy our wintery story! About: A549 cells on pine shaped carriers, dancing to magenta and being dosed with mulled wine. youtu.be/C30a5-rmrT4

Excited at attend @ELRIG_UK Drug Discovery 2023 today. Come and see us at Booth C7. We'll be demonstrating our SemaCyte Microcarriers Platform and show how it accelerates cell assaying workflows. #DD2023

We are launching our Early Adopter Programme! Get early access to our SemaCyte Microcarrier Platform to experience how this novel approach to adherent cell assaying can supercharge your drug discovery workflows. semarion.com/semarion-annou…

WEBINAR about SemaCyte Cell Assaying Microcarriers 🧫Ultra-miniaturized, mobile wells to move and freeze cells while preserving their adherent morphology 🚀Flexibility, speed, miniaturization for cell assays 📅 November 15 | 10:00-11:00 GMT | Register: events.teams.microsoft.com/event/45ef4cff…

Ever seen adherent cells move like this? Semarion is pushing the boundaries of what you can do with live cells! How: nextgen magnetic microcarriers. Why are we doing this? To Accelerate Cell Assays. Find our more: semarion.com #innovation #biotech #nanotechnology

Earlier this week, we attended @ELRIG_UK's Research & Innovation 2024. It was great to catch up with the teams at Nuclera and Semarion, as well as hear from Dr Dave Chapman (Centauri Therapeutics) about the Company's novel approach to combat antibiotic resistance.